Numerous studies have been conducted in the past decade evaluating the use of statins and other lipid therapies for reducing vascular events. These studies have impacted the area of stroke prevention.
For patients with established coronary artery disease, statins reduce the rate of stroke. High-dose statin treatment has also been found to reduce the rate of stroke in patients with recent cerebrovascular events and no evidence of heart disease. As a result, initiation of statin therapy for patients with stroke or TIA is now recommended in clinical guidelines. Whether agents that modulate high-density lipoprotein cholesterol are effective in reducing stroke is still the subject of clinical study.
Most patients with stroke or TIA should be treated with statins. The era of multimodal medical therapy for stroke prevention is now well established.
Address correspondence to Dr Seemant Chaturvedi, Wayne State University, 4201 Saint Antoine Street, 8C University Health Center, Detroit, MI 48201, firstname.lastname@example.org.
Relationship Disclosure: Dr Bhattacharya reports no disclosure. Dr Chaturvedi has received personal compensation for speaking or consulting activities from Abbott Vascular, AstraZeneca, Boehringer Ingelheim, and Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; has received personal compensation for expert witness testimony; and has received research support from Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, and Merck/Schering-Plough.
Unlabeled Use of Products/Investigational Use Disclosure: Drs Bhattacharya and Chaturvedi report no disclosure.